Proactive Investors
21 Jan 2026, 18:00 UTC · 35w ago
Verdict
Headline leans bullish. We score ATAI +0.90 across five claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.90strongly bullish
What the story claims
5 claims · scored −1 bearish … +1 bullish
Johnson & Johnson's Spravato reached a quarterly sales run rate exceeding $2 billion, with Q4 2025 sales rising 10% sequentially to $503 million.
More positive than 92% of claims this week
Jefferies analysts state that Spravato's success improves the perception of psychedelics as an investable space and suggests a warming regulatory environment.
Continue reading
5 related stories
More positive than 94% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 85% of claims this week
AtaiBeckley's BPL-003 candidate may have a competitive dosing advantage over Spravato, with a potential redosing cadence of every two to three months versus up to 52 times per year.
So whatSignificant improvement in patient burden could lead to higher market share and preference over the current market leader if approved.
More positive than 77% of claims this week
AtaiBeckley expects a 12-week dataset for BPL-003 in Q4 2026 and is planning a Phase IIa trial in Q1 2026.
More positive than 63% of claims this week
COMPASS Pathways expects further datasets for COMP360 in the first half of 2026 and plans a potential rolling submission following Phase III TRD data.
So whatNear-term regulatory filings and data readouts are primary drivers for biotech stock valuations.
More positive than 63% of claims this week
Which stocks this story touches
More positive than 94% of ticker scores this week
Named as a direct beneficiary of Spravato's success with a promising Phase II program and a potentially superior dosing cadence.
More positive than 86% of ticker scores this week
Spravato sales rose 10% sequentially and the drug is on track to meet high annual sales guidance.
More positive than 73% of ticker scores this week
Expected to benefit from a shifting commercial landscape and upcoming Phase III data for its psilocybin candidate.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
18m ago
Invezz
1h ago
More positive than 15% of relationship scores this week
[mutual] Both companies compete in the commercial landscape for psychedelic therapies targeting treatment-resistant depression.
More positive than 15% of relationship scores this week
[mutual] Both companies are developing psychedelic candidates (BPL-003 and COMP360) for the treatment of depression.
+90.9%
Price agrees with the score
$7.35 vs $3.85 close before publication (Jan 20) · not market-adjusted
ATAI chart →
